Allarity Therapeutics Q2 FY26 net loss widens to $3.41 million; comprehensive loss narrows to $3.67 million

PUBT · 1d ago
Allarity Therapeutics Q2 FY26 net loss widens to $3.41 million; comprehensive loss narrows to $3.67 million
  • Allarity Therapeutics posted a Q2 net loss of USD 3.41 million, widening from USD 2.32 million a year earlier; loss per share rose to USD 0.21.
  • Operating loss narrowed to USD 2.67 million from USD 4.13 million, as R&D fell 42% to USD 1.35 million and G&A dropped 26.82% to USD 1.33 million.
  • Cash and restricted cash climbed to USD 26.9 million at June 30, up from USD 14.7 million a year earlier; operating cash outflow was USD 2.6 million.
  • Completed a Phase 3-ready stenoparib API manufacturing campaign in July, with all payments booked as prepaid expenses and no additional cash outlays expected.
  • USPTO granted a U.S. patent covering the stenoparib DRP companion diagnostic through April 2042; CLIA certification secured for its in-house DRP testing lab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140800PRIMZONEFULLFEED1001257591) on August 14, 2026, and is solely responsible for the information contained therein.